FDA approves Eisai's Dacogen

WOODCLIFF LAKE, N.J. The Food and Drug Administration has approved a five-day dosing regimen for an injectable drug made by Eisai for treating bone marrow disease, Eisai announced.

The drug, Dacogen (decitabine) treats myelodysplastic syndromes, which alter the production of blood cells. Eisai said the new option allows outpatient dosing that will provide reduced infusion time.

The drug can be administered via IV for one hour a day for five days ever four weeks. The previous regimen required infusion for three hours repeated every eight hours for three days, repeated every six weeks.